Francesca Barone, Chief Scientific Officer at Candel Therapeutics, Inc. (CADL), sold 23,447 shares at $10.06 ($236K) on 2026-06-29, disclosed to the SEC on 2026-07-01.
Scheduled sale ($236k) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| CADL | SELL | 2025-01-10 | $225K | — | Filing → |
| CADL | SELL | 2024-12-03 | $201K | — | Filing → |
| CADL | SELL | 2024-07-19 | $182K | — | Filing → |